NetworkNewsBreaks – CytoDyn Inc. (CYDY) President and CEO Featured in Uptick Newswire’s Stock Day Podcast

Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced the featured interview of its President and CEO Nader Z. Pourhassan, Ph.D. with Stock Day’s Everett Jolly. Jolly initiated the discussion by asking about CytoDyn’s PRO 140. The company’s flagship product is a humanized IgG4 monoclonal antibody that is designed to bind to cellular receptor CCR5, which plays various roles with implications in HIV, tumor metastasis and immune signaling. Pending FDA approval, which the company hopes to secure in Q4 2019, Pourhassan indicates that PRO 140 may be available to the public in 2020.  “Most biotech companies, when they finish the biologic application, they have an 85% chance to get approved. 9 out of 10 who don’t get approved is because of the safety of the product. Our product has received fast track designation due to having great safety among all of the approved drugs,” Nader Z. Pourhassan, Ph.D., president and CEO of CytoDyn, stated in the news release.

To hear the Stock Day Podcast featuring the interview, visit http://nnw.fm/kYJU8

To view the full press release, visit http://nnw.fm/4Q7xo

About CytoDyn

CytoDyn is a biotechnology company developing innovative treatments for multiple therapeutic indications based on PRO 140 (leronlimab), a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 plays a key role in the ability of HIV to enter and infect healthy T-cells.  The CCR5 receptor is also implicated in tumor metastasis and in immune-mediated illnesses such as graft-vs-host disease (GvHD) and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with PRO 140 in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. The Company plans to seek FDA approval for PRO 140 in combination therapy and plans to complete the filing of a Biological License Application (BLA) in the first quarter of 2019 for that indication. CytoDyn is also conducting a Phase 3 investigative trial with PRO 140 as a once-weekly monotherapy for HIV-infected patients, and plans to initiate a registration-directed study of PRO 140 monotherapy indication, which if successful, could support a label extension. Clinical results to date from multiple trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, results from a Phase 2b clinical trial demonstrated that PRO 140 monotherapy can prevent viral escape in HIV-infected patients, with some patients on PRO 140 monotherapy remaining virally suppressed for more than four years. CytoDyn is also conducting a Phase 2 trial to evaluate PRO 140 for the prevention of GvHD and expects to initiate clinical trials with PRO 140 in metastatic triple-negative breast cancer in 2018. For more information, visit the company’s website at www.CytoDyn.com

More from NetworkNewsBreaks

NetworkNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Launches Comprehensive POS Solution, Aptito NetworkNewsBreaks – Foresight Autonomous Holdings Ltd.’s (NASDAQ: FRSX) (TASE: FRSX) QuadSight Wins 2019 CES Innovation Award NetworkNewsBreaks – Plus Products Inc. (CSE: PLUS) Brings to Market its Cranberry & Shortbread Gummies: 2018 Holiday Limited Edition

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire has received compensation from CytoDyn Inc. for providing certain investor relations, marketing and social media services, including the preparation of this report, and expects to receive additional compensation for such services in the future. This compensation includes a monthly program fee.

Other Press Releases

Harvey Weinstein breaks with his criminal defense lawyer

Jan 18, 2019

NEW YORK — Harvey Weinstein is recasting his legal team a month after losing a hard-fought bid to get his sexual assault case thrown out. Weinstein and high-profile defense attorney Benjamin Brafman said in a statement Thursday that they "have agreed to part ways" and that new lawyers would be introduced next week. The disgraced movie mogul's trial is tentatively scheduled for May 6. He is charged with raping an unidentified female acquaintance in 2013 and performing a forcible sex act on a different woman in 2006. A conviction could put him in prison for the rest of his life....

UFC obliging troubled Greg Hardy's desire for 2nd chance

Jan 18, 2019

NEW YORK — Greg Hardy's eyes popped as he saw his name in bold print on the oversized placard that identified him as a UFC fighter. "That's dope! It's got my Twitter thing on it," Hardy said with a laugh. Yes, his Twitter handle @greghardyjr was printed underneath his name to let fans know how to find the hulking heavyweight on social media. UFC enthusiasts and social media pundits had already pounced on the disgraced former NFL defensive end: — "he can beat up women that's for sure." — "why is this woman beater in the UFC?" — "which woman...

Netflix has no plans to cut 'Bird Box' scene despite outcry

Jan 18, 2019

NEW YORK — Netflix's post-apocalyptic survival film "Bird Box" is drawing criticism for using footage of a real fiery train disaster but the streaming giant has no plans to remove it. The footage concerns a 2013 tragedy in the Quebec town of Lac-Megantic when an unattended train carrying crude oil rolled down an incline, came off the tracks and exploded into a massive ball of fire, killing 47 people. Netflix licensed the footage of the disaster from the stock image vendor Pond 5 and used it in "Bird Box" in an early TV news montage to set up its horrific...

Ex-CBS CEO Les Moonves to challenge severance denial

Jan 18, 2019

NEW YORK — Former CBS CEO Les Moonves is fighting the company's decision to deny his $120 million severance package following his firing over sexual misconduct allegations. Moonves is demanding binding arbitration proceedings to challenge the decision, CBS announced in a filing Thursday with the Security Exchange Commission. The company's board of directors denied Moonves his severance last month after concluding that he violated company policy and did not cooperate with an investigation into the sexual misconduct allegations. Moonves, one of television's most influential figures, was ousted in September after allegations from women who said he subjected them to mistreatment...

Pulitzer Prize-winning poet Mary Oliver dies at 83

Jan 18, 2019

NEW YORK — Mary Oliver, the Pulitzer Prize-winning poet whose rapturous odes to nature and animal life brought her critical acclaim and popular affection, has died. She was 83. Bill Reichblum, Oliver's literary executor, said she died Thursday at her home in Hobe Sound, Florida. The cause of death was lymphoma. "Thank you, Mary Oliver, for giving so many of us words to live by," Hillary Clinton wrote in a tweet. Ava DuVernay quoted from Oliver's poem "Praying" and fans online shared their favorite lines. Author of more than 15 poetry and essay collections, Oliver wrote brief, direct pieces that...

Hollywood in five is your 5 minutes read of Hollywood news with continual updated coverage.

Contact us: sales@hollywoodinfive.com